Dimensional Fund Advisors LP Lowers Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Dimensional Fund Advisors LP trimmed its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 717,714 shares of the company's stock after selling 7,403 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.96% of SpringWorks Therapeutics worth $25,931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC raised its position in shares of SpringWorks Therapeutics by 30.8% during the fourth quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company's stock worth $2,231,000 after acquiring an additional 14,548 shares during the last quarter. Schroder Investment Management Group raised its position in shares of SpringWorks Therapeutics by 93.6% during the fourth quarter. Schroder Investment Management Group now owns 168,209 shares of the company's stock worth $6,113,000 after acquiring an additional 81,314 shares during the last quarter. Vanguard Group Inc. raised its position in shares of SpringWorks Therapeutics by 6.6% during the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock worth $258,650,000 after acquiring an additional 445,593 shares during the last quarter. BIT Capital GmbH lifted its stake in shares of SpringWorks Therapeutics by 18.7% in the 4th quarter. BIT Capital GmbH now owns 53,539 shares of the company's stock valued at $1,934,000 after purchasing an additional 8,429 shares during the period. Finally, Platinum Investment Management Ltd. acquired a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at about $1,694,000.

SpringWorks Therapeutics Stock Performance

NASDAQ:SWTX traded down $0.10 during trading on Monday, reaching $46.17. The company's stock had a trading volume of 2,420,671 shares, compared to its average volume of 2,000,606. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -13.27 and a beta of 0.77. The firm has a 50 day moving average of $44.35 and a 200-day moving average of $41.76. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. Equities research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Insider Activity at SpringWorks Therapeutics

In related news, Director Daniel Lynch sold 47,600 shares of SpringWorks Therapeutics stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $60.22, for a total transaction of $2,866,472.00. Following the sale, the director now owns 82,944 shares of the company's stock, valued at approximately $4,994,887.68. This trade represents a 36.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saqib Islam sold 29,328 shares of SpringWorks Therapeutics stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $60.30, for a total value of $1,768,478.40. Following the completion of the sale, the chief executive officer now directly owns 1,034,625 shares in the company, valued at approximately $62,387,887.50. The trade was a 2.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 158,016 shares of company stock valued at $9,102,946. Corporate insiders own 7.83% of the company's stock.

Analyst Ratings Changes

SWTX has been the subject of a number of research analyst reports. TD Cowen reiterated a "hold" rating and issued a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Barclays reiterated an "equal weight" rating and issued a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Evercore ISI downgraded SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Wedbush reiterated a "neutral" rating and issued a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Finally, Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a report on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, SpringWorks Therapeutics has an average rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.